Haemonetics Corporation (NYSE:HAE – Get Free Report)’s stock price hit a new 52-week high during trading on Monday . Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. Barrington Research cut their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating and set a $84.00 price target on shares of Haemonetics in a research note on Friday, June 26th. North Peak Capital Management LLC boosted its holdings in shares of Haemonetics by 204.4% during the fourth quarter.